Rebate ban glooms pharmaceutical industry

Published: 2010-05-04 07:00:00

Updated: 2010-05-04 07:00:00

Prospects have been grim for Korean firms, as they are getting pressed by multinationals' increasing market presence and the government's pressure to lower drug costs. Generic drugs have long been the competitive edge for local makers, but even they are set to lose steam once doctors choose to pr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK